Skip to main content
Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
28.86
+0.54 (1.91%)
At close: Dec 5, 2025, 4:00 PM EST
28.31
-0.55 (-1.91%)
After-hours: Dec 5, 2025, 6:59 PM EST

Caris Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22
Revenue
649.06412.26306.13258.49
Revenue Growth (YoY)
112.02%34.67%18.43%-
Cost of Revenue
258.46231.83214.87178.46
Gross Profit
390.6180.4391.2680.02
Selling, General & Admin
376.51326.05296.04294.51
Research & Development
94.43111.5114.77101.27
Operating Expenses
470.95437.55410.81395.78
Operating Income
-80.34-257.12-319.55-315.76
Interest Expense
-58.76-50.03-31.61-26.68
Interest & Investment Income
10.457.1211.260.95
Other Non Operating Income (Expenses)
-40.4118.149.420.66
EBT Excluding Unusual Items
-169.06-281.89-330.5-320.83
Other Unusual Items
-17.93--10.92-
Pretax Income
-186.99-281.89-341.42-320.83
Net Income
-186.99-281.89-341.42-320.83
Preferred Dividends & Other Adjustments
494.8796.37121.1179
Net Income to Common
-681.86-378.26-462.53-399.83
Shares Outstanding (Basic)
105353533
Shares Outstanding (Diluted)
105353533
Shares Change (YoY)
201.21%1.59%4.73%-
EPS (Basic)
-6.48-10.66-13.24-11.98
EPS (Diluted)
-6.48-10.66-13.24-11.98
Free Cash Flow
-14.01-253.64-298.42-327.96
Free Cash Flow Per Share
-0.13-7.15-8.54-9.83
Gross Margin
60.18%43.77%29.81%30.96%
Operating Margin
-12.38%-62.37%-104.38%-122.16%
Profit Margin
-105.05%-91.75%-151.09%-154.68%
Free Cash Flow Margin
-2.16%-61.52%-97.48%-126.88%
EBITDA
-52.95-208.21-270.55-267.5
EBITDA Margin
-8.16%-50.50%-88.38%-103.49%
D&A For EBITDA
27.3948.914948.25
EBIT
-80.34-257.12-319.55-315.76
EBIT Margin
-12.38%-62.37%-104.38%-122.16%
Revenue as Reported
649.06412.26306.13258.49
Advertising Expenses
-1.20.61
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q